Nektar Therapeutics (NKTR): Price and Financial Metrics
NKTR Price/Volume Stats
| Current price | $1.32 | 52-week high | $1.75 |
| Prev. close | $1.38 | 52-week low | $0.41 |
| Day low | $1.29 | Volume | 1,054,000 |
| Day high | $1.37 | Avg. volume | 2,151,004 |
| 50-day MA | $1.01 | Dividend yield | N/A |
| 200-day MA | $0.68 | Market Cap | 242.38M |
NKTR Stock Price Chart Interactive Chart >
Nektar Therapeutics (NKTR) Company Bio
Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
Latest NKTR News From Around the Web
Below are the latest news stories about NEKTAR THERAPEUTICS that investors may wish to consider to help them evaluate NKTR as an investment opportunity.
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual MeetingNektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting demonstrating that NKTR-255 significantly enhanced the cytotoxicity of expanded Natural Killer (NK) cells when combined with obinutuzumab against rituximab-resistant BL cells and significantly improved the survival of mice xenografted with Raji-4RH compa |
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call TranscriptNektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript November 7, 2023 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $-0.18. Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is […] |
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 LossNektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line. |
NKTR Price Returns
| 1-mo | 46.67% |
| 3-mo | 159.33% |
| 6-mo | 178.60% |
| 1-year | 64.88% |
| 3-year | -93.53% |
| 5-year | -95.91% |
| YTD | 133.63% |
| 2023 | -75.00% |
| 2022 | -83.27% |
| 2021 | -20.53% |
| 2020 | -21.24% |
| 2019 | -34.33% |
Continue Researching NKTR
Want to do more research on Nektar Therapeutics's stock and its price? Try the links below:Nektar Therapeutics (NKTR) Stock Price | Nasdaq
Nektar Therapeutics (NKTR) Stock Quote, History and News - Yahoo Finance
Nektar Therapeutics (NKTR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...